But wait, it gets worse. According to Drugwatch, this widely prescribed medication for severe asthma and chronic hives has other terrifying side effects, which include: heart attacks, cancer, pulmonary hypertension, mini strokes, blood clots in the lungs, and deep vein thrombosis (DVT). Also, Xolair is administered by injection and the risk of anaphylactic shock — a life-threatening allergic reaction — is so severe patients are required to wait in their doctors’ office for two hours just in case.
Yikes! So after all the resources they poured into Xolair, Genentech’s and Novartis’ unholy alliance resulted in a product that few people need and that no one in their right mind could possibly want to buy. So now what?
How Big Pharma Sold Xolair With Bribes, Kickbacks And Hottie Sales Reps.
So, how the heck do you get people to buy an over-priced, high-maintenance and potentially lethal drug like Xolair? Have young, attractive pharmaceutical sales reps bearing gifts visit doctors’ offices and gently persuade them to write prescriptions “off-label.” Because who cares what the fuddy-duddy folks at the FDA list as “approved uses?” This is America, goddammit, and doctors can write whatever the hell prescriptions they want. And if you don’t think those Big Pharma sales reps have any influence on what your doctor prescribes, then you’ve never seen that hilarious “Julie’s Here” scene with Heather Locklear from Scrubs season 2, episode #7.
No wonder Scrubs‘ fictional Dr. Cox kept ranting about Big Pharma destroying the field of medicine while trying not to go gaga over Julie. And when sex appeal’s not enough to get a doctor to write a Xolair prescription off-label, those sweet office gifts, fancy dinners, paid speaking engagements, and phony awards may do the trick.
That may sound crazy, but Alternet’s Martha Rosenberg reports on two pharmaceutical sales reps who sold Xolair for Genentech and Novartis until their consciences forced them to blow the whistle. Frank Garcia and Allison Kelly filed a 400-page complaint under the False Claims Act 11 years ago that alleges a “scheme of kickbacks and bribes, misinformation about Xolair’s approved uses and risks and insurance fraud.”
Novartis, Genentech and Roche (which acquired Genentech in 2009) “determined as early as 2003 that they would never succeed in transforming Xolair into a blockbuster or near-blockbuster drug unless they broke the law,” say their complaints. “And that is exactly what they have knowingly done, by aggressively and illegally marketing Xolair, on a national basis, to induce HCPs [health care providers] to prescribe Xolair for wide-ranging use—despite the drug’s very limited efficacy and proven threats to patient safety.”
While doctors can legally prescribe drugs for “off-label” (non-FDA authorized) uses, pharmaceutical companies are barred from off-label marketing. Yet Garcia and Kelly alleged that Genentech and Novartis expected them to do the following:
- Use the term “active asthma” to get around the FDA’s “moderate to severe persistent asthma” limitation.
- Tell doctors patients didn’t really need to be monitored for two hours for anaphylactic reactions and that some could even inject Xolair at home.
- Call on pediatricians and falsely claim that the drug was safe to prescribe for children under 12.
- Show bogus medical studies — usually by doctors bought and paid for by Novartis and Genentech — that recommend non-FDA approved uses for Xolair.
- Commit fraud by “helping” medical staff with coding and reimbursement — including “upcoding” prescriptions at higher rates — from Medicare and health insurance companies.
- Visit medical practices in low-income neighborhoods where patients were more likely to be on Medicaid or Medicare. (We, the taxpayer, spent $412 million on prescriptions for Xolair from 2004-2011, according to Alternet.)
Garcia and Kelly also claim doctors and staff received bribes and kickbacks for prescribing Xolair, including:
- American Express travelers checks, tickets to events, fancy dinners out, and “even a trip to the Bahamas.”
- Gifts of expensive medical and office equipment.
- Payments to doctors for conducting “studies” with favorable findings, serving on phony “advisory boards,” all-expense paid trips for so-called speaking engagements; and various cash grants.
- “Buy and bill” arrangements with pharmacies that would get kickbacks if a patient’s insurance or Medicare refused to cover a prescription.
- Hire and train high-profile doctors as “Key Opinion Leaders” to speak highly of Xolair (Garcia and Kelly claim one got a whopping $100,000 between 2002 and 2003).
Frank Garcia and Allison Kelly allege Novartis and Genentech even paid patients to sing the praises of Xolair in exchange for a free supply, plus cash and all-expenses paid trips for speaking at events. But here’s a truly scary detail that sticks out in my mind after my chat with Frank Garcia. Because people in doctors’ offices are so danged busy, these pharmaceutical sales reps often had to do the Xolair injections themselves.
“We were taught to inject patients. It was so time consuming for their office staff. We had to teach them how to upcode, how to claim it as almost a chemotherapy drug [in terms of complexity and reimbursement rates] They wanted us to go to the hospitals where they did the intravenous — Imagine a rep is going to inject your child. And he’s not even a doctor or a nurse. No scrubs, just in our suits, that’s how we were doing it.”
Garcia then sheepishly adds:
“I was known for fainting when I see shots, so Allison would have to do it for me.”
Oh, and guess how the sales reps were trained to inject Xolair?
“You know how they trained us? This medication is by injection, right? They were injectables. They trained us not only to make the medication to make it a liquid form, they trained us on oranges. We had a table full of oranges and we had to inject them.”
Xolair Case Dismissed On A Technicality.
Unfortunately, the False Claims case against Novartis and Genentech has hit what the whistleblowers’ attorney Tim Cornell describes to Corporate Crime Reporter as some “bumps in the road.” The DOJ was investigating the case but then abruptly declined it in 2011. Since False Claims Act filings become public if the government chooses not to intervene, Allison Kelly bowed out for fear of losing her job at Novartis.
The case then wound up before a federal court in Boston, where Judge William Young dismissed the whistleblowers’ (referred to as the relators) claims last year. The court acknowledged that the illegal marketing and kickbacks had likely taken place. Alas, Judge Young also ruled that the whistleblowers couldn’t prove any fraud against the US government (i.e. the alleged Medicare upcoding), a key component for a false claims case.
Garcia’s attorney Tim Cornell, of course, has filed an appeal because the evidence exists, Judge Young just refused to admit it in court.
“Judge Young blocked the relators from being able to file their 400-page complaint with these detailed allegations. He then went on to rule on the existing complaint. In the existing complaint, he said that it shows probable fraud, but there is not enough in the allegations. The Judge says — if you could show me one doctor who received government money and what you alleged to be kickbacks, then I would let this pass. But you haven’t done this.”
As Martha Rosenberg points out in her Alternet article, other Big Pharma companies, including Pfizer, GlaxoSmithKline, Johnson & Johnson, Bristol-Myers Squibb, Eli Lilly and Victory Pharma have also been charged with illegal marketing. Yet — like the big banks that committed fraud and tanked the economy back in 2008 — Big Pharma never seem to get punished or held accountable. Caroline Beaton from the Huffington Post explains this happens for a variety of reasons:
- Plaintiffs often settle cases: Those who’ve been wronged by Big Pharma often settle out of court because they lack the financial resources required to go to trial. For a mere pittance that barely cuts into their massive profits, these companies get to avoid the bad publicity a trial would bring.
- The US Supreme Court doesn’t hold Big Pharma liable for generic drugs: Thanks to a series of little-known SCOTUS rulings from 2011-2013, generic drug manufacturers are exempt from liability for just about every type of claim against them, even when they’re deceptive or negligent. Generic drugs are about 80 percent of the market.
- The FDA fast-tracks drug approvals to encourage “innovation”: Whether the US government wants to shed the bad rap pro-business folks lay on it, cater to deep-pocketed Big Pharma friends, or just wants to save money, cutting corners with time and resources to get drugs out faster is bad news for consumers.
Oh, and the fact that FDA commissioner Dr. Robert M. Califf has, according to The New York Times, “deeper ties to the pharmaceutical industry than any FDA commissioner in recent memory” surely has something to do with it.